Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey

View through CrossRef
Summary.  Frequent evaluation of haemophilia treatment is necessary to improve patient care. The 2010 Practice Patterns Survey (PPS) investigated current trends in haemophilia treatment in the United States, as reported by nurses. The aim was to document practice patterns for haemophilia A and haemophilia B Survey questionnaires were sent to nurses at haemophilia treatment centres (HTCs) across the United States. Seventy‐one of 126 HTCs (56%) responded to the survey. Factor dosage across treatment modalities ranged from 20 to 50 IU kg‐1 for severe haemophilia A. Dosage for severe haemophilia B was more variable (<40 to >100 IU kg‐1). On‐demand dosing regimens were inconsistent for haemophilia A and more so for haemophilia B. Rates of adherence to prescribed treatment were similar for both haemophilia types (∼80%). The main barrier to adherence was identified as inconvenience. More bleeding episodes occurred in adults (16.6 bleeding episodes per year) with severe haemophilia A than in younger patients (11.3 bleeding episodes per year) before switching patients to prophylaxis. For both haemophilia types, most patients who switched from prophylaxis to on‐demand treatment were aged 13–24 years; these patients also had the lowest adherence (60–71%). More paediatric patients with severe haemophilia A and inhibitors (53%) received prophylactic bypassing therapy than their haemophilia B counterparts (38%). Adults with severe haemophilia A faced challenges in relation to co‐morbidities and long‐term care. This PPS provides insights into previously unexplored aspects of haemophilia care that will serve to increase awareness and promote discussion of current issues affecting haemophilia patient care.
Title: Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey
Description:
Summary.
  Frequent evaluation of haemophilia treatment is necessary to improve patient care.
The 2010 Practice Patterns Survey (PPS) investigated current trends in haemophilia treatment in the United States, as reported by nurses.
The aim was to document practice patterns for haemophilia A and haemophilia B Survey questionnaires were sent to nurses at haemophilia treatment centres (HTCs) across the United States.
Seventy‐one of 126 HTCs (56%) responded to the survey.
Factor dosage across treatment modalities ranged from 20 to 50 IU kg‐1 for severe haemophilia A.
Dosage for severe haemophilia B was more variable (<40 to >100 IU kg‐1).
On‐demand dosing regimens were inconsistent for haemophilia A and more so for haemophilia B.
Rates of adherence to prescribed treatment were similar for both haemophilia types (∼80%).
The main barrier to adherence was identified as inconvenience.
More bleeding episodes occurred in adults (16.
6 bleeding episodes per year) with severe haemophilia A than in younger patients (11.
3 bleeding episodes per year) before switching patients to prophylaxis.
For both haemophilia types, most patients who switched from prophylaxis to on‐demand treatment were aged 13–24 years; these patients also had the lowest adherence (60–71%).
More paediatric patients with severe haemophilia A and inhibitors (53%) received prophylactic bypassing therapy than their haemophilia B counterparts (38%).
Adults with severe haemophilia A faced challenges in relation to co‐morbidities and long‐term care.
This PPS provides insights into previously unexplored aspects of haemophilia care that will serve to increase awareness and promote discussion of current issues affecting haemophilia patient care.

Related Results

A preliminary application of a haemophilia value framework to emerging therapies in haemophilia
A preliminary application of a haemophilia value framework to emerging therapies in haemophilia
AbstractIntroductionEmergence of new therapies are anticipated to improve clinical outcomes and quality of life of persons with haemophilia. Challenges in conducting randomized cli...
A transgender person with haemophilia
A transgender person with haemophilia
Abstract Introduction Transgender people face many obstacles to accessing healthcare but cultural changes are likely to i...
Haemophilia care in Iraq; a multi-centre study
Haemophilia care in Iraq; a multi-centre study
Objectives: To evaluate the level of care available to haemophilia patients. Method: The descriptive, retrospective analytical study was conducted from December 15, 2020, to March...
Haemophilia treatment in 2030
Haemophilia treatment in 2030
IntroductionLooking into the future is difficult and sometimes hazardous. A reliable look into haemophilia treatment in 2030 should be based on history and contemporary progress as...
Normalisation of Haemostasis in Haemophilia A
Normalisation of Haemostasis in Haemophilia A
Haemophilia A (Factor VIII [FVIII] levels ≤40 IU/dL) is a chronic condition with consequences beyond bleeding complications. Many people with haemophilia A (PwHA) experience pain, ...
Preventing bleeds by treatment: new era for haemophilia changing the paradigm
Preventing bleeds by treatment: new era for haemophilia changing the paradigm
IntroductionCoagulation products have allowed patients with severe haemophilia to lead a normal life. This is, however, only true for patients who received an early diagnosis and c...
UKHCDO gene therapy taskforce: Guidance for implementation of haemophilia gene therapy into routine clinical practice for adults
UKHCDO gene therapy taskforce: Guidance for implementation of haemophilia gene therapy into routine clinical practice for adults
AbstractIntroduction2022 was a landmark year with two adeno‐associated viral vectors (AAVs) receiving conditional marketing authorization from EMA for the treatment of persons with...

Back to Top